University of Washington
K-240B Health Sciences Building
Medical Genetics, Box 357720
Seattle, WA 98195-7720
Phone: (206) 221-3973
Phone: (206) 543-0109
FAX: (206) 685-8675
E-mail: lieber00@u.washington.edu
Cancer gene therapy
Wang H, Liaw YC, Stone D, Kalyuzhniy O, Amiraslanov I, Tuve S, Verlinde CL, Shayakhmetov D, Stehle T, Roffler S, Lieber A. (2007) Identification of CD46 binding sites within the adenovirus serotype 35 fiber knob. Journal of Virology, 2007 Sep 26; [Epub ahead of print]
Tuve S., Chen, B-M., Liu, Y., Cheng, T-L, Touré, P., Sow, p.S., Feng, Q., Kiviat, N., Ni, S., Li, ZY., Roffler, S.R., Lieber, A. (2007) Combination of tumor-site located CTLA-4 blockade and systemic Treg depletion induces anti-tumor immunity but not autoimmunity. Cancer Research, 67: 5929-5939
Wang, H-J., Leege, T., Shayakhmetov, D., Li, Q., Papayannopoulou, T., Stamatoyannopolous, G., Lieber, A. (2005) A capsid-modified helper-dependent adenovirus vector containing the beta-globin locus control region displays a non-random integration pattern and allows for stable, erythroid-specific gene expression. Journal of Virology, 79: 10999-1013
Sova, P. Ren, X-W., Ni, S. Bernt, K., Mi, J., Kiviat, N., Lieber, A. (2004) A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Molecular Therapy, 9: 496-509
Gaggar, A., Shayakhmetov, D.M., Lieber, A. (2003) CD46 is a cellular receptor for group B adenovirus. Nature Medicine, 9: 1408-12
Steinwaerder, D.S., Carlson, C.A., Otto, D.L., Li, Z-Y., Ni, S., Lieber, A. (2001) Tumor specific gene expression in hepatic metastases by a replication-activated adenovirus vector. Nature Medicine, 7: 2140-243